Noom To Streamline Access to Zepbound® Vials with Noom GLP-1 Companion Through Integration with LillyDirect® Pharmacy Provider
This integration evolves Noom’s comprehensive approach to weight management by enabling a streamlined solution for members ...
Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025
Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...
Why cheaper alternatives to weight-loss drugs like Wegovy, Zepbound will be tougher to get
The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...
Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly
It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug ...
Sesame, America’s Low-Cost Leader in Healthcare, Streamlines Access for Eligible Patients to Lilly’s Obesity Medicine Zepbound
Streamlined access to authentic, FDA-approved, rigorously-tested Zepbound comes from Sesame’s direct integration with Gifthealth. Zepbound is the first and only FDA-approved dual glucagon-like peptide ...
Eli Lilly: Growth With Higher Margins
Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...
Becker's Hospital Review13d
Zepbound, Wegovy fail to justify prices: Study
A new study suggests blockbuster weight loss drugs Wegovy and Zepbound are not cost-effective at their current prices, despite the proven health benefits. The study, published in JAMA Health Forum and ...
Two telehealth firms turn to branded Zepbound as restrictions loom on copies
Telehealth firms Teladoc and LifeMD said on Thursday they had signed an agreement to offer Eli Lilly's weight-loss drug Zepbound to self-paying patients, ahead of restrictions on selling copies known ...